 AstraZeneca PLC LSE:AZN, and its US peer Merck Co, announced that the US Food and Drug Administration FDA will allow more time to review the new drug application for its cancer drug, Lynparza. The pharmaceuticals giant said the FDA will extend the Prescription Drug User Fee Act PDUFA date by three months to provide further time for a full review of the supplementary new drug application for Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment ofmetastatic castration-resistant prostate cancer. 